Pharvaris N.V.
PHVS Nasdaq· Pharmaceutical Preparations
Last close · Nov 9, 2026
$34.47
Latest quarter · Q2 '25 results quarter ended Jun 30, 2025 · vs Q2 '24
| Line | Q2 '24 | Q2 '25 | Change (y/y) |
|---|---|---|---|
| Net income | −$32.0M | −$51.5M | — |
| Diluted EPS | −$0.59 | −$0.94 | — |
Key numbers, fiscal 2025
Market cap
$2.0B
P/E
—
Revenue
$7.4M
Net income
−$198M
Free cash flow
−$155M
Operating margin
−2,658.2%
Pharvaris N.V. in 30 seconds fiscal 2025
Are shareholders being diluted?
+9.5%
Somewhat. The share count rose 9.5% last year, so each share owns a little less.
Does it make a profit?
$140M R&D
Not yet: it has no meaningful sales. It spent $140M on research and development, 69% of its operating costs.
How long would its cash last?
2.2 yrs
Comfortably. It burns $155M a year and holds $343M, about 2.2 years at that pace.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Pharvaris N.V. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 2, 2026
- Legal name
- Pharvaris N.V.
- CIK
- 0001830487
Pharvaris N.V. · PHVS · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | −$0.3M | −$0.0M | $0.2M | $5.9M | $7.4M |
| Revenue growth | — | — | — | 2,336.9% | 24.5% |
| Net interest income | −$0.3M | −$0.0M | $0.2M | $5.9M | $7.4M |
| Operating margin | 15,946.1% | 470,491.7% | −44,461.4% | −2,420.6% | −2,658.2% |
| Net income | −$50.5M | −$80.2M | −$109M | −$145M | −$198M |
| Net margin | 15,961.0% | 474,714.8% | −44,928.5% | −2,454.0% | −2,688.6% |
| Diluted EPS | −$1.66 | −$2.39 | −$2.84 | −$2.68 | −$3.35 |
| Cash | |||||
| Cash from operations | −$52.7M | −$70.6M | −$101M | −$130M | −$155M |
| Capital expenditure | $0.2M | $0.1M | $0.1M | $0.6M | $0.2M |
| Free cash flow | −$52.9M | −$70.7M | −$101M | −$131M | −$155M |
| FCF margin | 16,719.5% | 418,459.8% | −41,483.0% | −2,206.2% | −2,100.0% |
| Share count change | 527.0% | 10.4% | 14.3% | 40.7% | 9.5% |
| Debt and strength | |||||
| Cash and short-term investments | $237M | $173M | $432M | $292M | $343M |
| Shareholders' equity | $232M | $159M | $424M | $278M | $319M |
| Interest coverage | −159.5x | −4,704.9x | — | — | — |
| Returns and quality | |||||
| Return on equity | −28.9% | −41.0% | −37.4% | −41.3% | −66.4% |
| Return on tangible equity | −21.8% | −50.4% | −25.7% | −52.2% | −62.2% |
Insider trades 12 months
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$32.7M
11 insiders
Of sales under plans
48%
$15.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Pharvaris N.V. · PHVS · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001830487). Latest version: stoqly.net/companies/phvs. Data updated November 9, 2026. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.